Mylan MYL

  1. All
  2. Commentary
  3. Headlines
    1. EU approves Mylan purchase of Abbot generics, subject to conditions

      Headlines

      Wed, 28 Jan 2015

      BRUSSELS, Jan 28 (Reuters) - The European Commission approved on Wednesday the acquisition of Abbot Laboratories' non-U.S. Developed Markets Specialty and Branded Generics Business (Abbott EPD-DM) by...

    2. 2014's Biggest Stock Winners: Is There Any Gas Left in the Tank?

      Headlines

      Wed, 7 Jan 2015

      as a smaller player within the generics space, doesn't have the scale to compete with giants such as Teva TEVA and Mylan MYL . The stock's valuation isn't attractive, either, trading well above Krempa's $72 fair value estimate. Royal

    3. Mylan Posts Strong 3Q and Still Expects to Gain Tax Benefit From Abbott Pharma Inversion

      Commentary

      Fri, 31 Oct 2014

      changes to our fair value estimate for Mylan even after the company's reported ..... moderately surpassed our expectations. Mylan also benefited from some nonrecurring ..... over quality-control issues during Mylan 's acquisition of that firm's Agila

    4. Sanofi Issues Disappointing Diabetes Guidance, Leading to a Lower Fair Value Estimate

      Commentary

      Tue, 28 Oct 2014

      deteriorating pricing will likely remove some biosimilar threats to Lantus over the long term. We believe both Merck and Mylan will reevaluate launching biosimilars. Nevertheless, Lilly's biosimilar will likely still reach the market in Europe

    5. Abbott Posts Solid 3Q, but Vascular Devices Continues to Struggle

      Commentary

      Wed, 22 Oct 2014

      established pharmaceuticals segment. Now that the branded generics business in mature developed markets is being sold to Mylan , Abbott is set for robust growth focused on the emerging markets. While we do not expect that 13% growth is sustainable

    6. New U.S. Treasury's Plan to Limit Inversions Pressures Low-Tax Targets

      Commentary

      Tue, 23 Sep 2014

      specifically targets "spinversions" makes the Mylan /Abbott subsidiary deal less likely to proceed, hurting Mylan 's valuation. In this case, the valuation of Mylan (not Abbott) would be under pressure, given

    7. Mylan Will Likely Need Key Product Approvals to Meet Uncertain Year-End Outlook

      Commentary

      Thu, 7 Aug 2014

      While Mylan ’s 8% revenue growth during the quarter ..... competition on EpiPen as a substantial hurdle for Mylan , we stand by our narrow moat rating for the company. During the quarter, Mylan ’s sales grew 8% through 6% constant

    8. Abbott Labs Delivers Slightly Better-Than-Expected 2Q

      Commentary

      Wed, 16 Jul 2014

      acquisitions of CFR and Veropharm, along with the divestment of Abbott's established pharmaceuticals in the developed markets to Mylan . Importantly, Abbott made progress on profitability as it held manufacturing and operating costs down. We continue to

    9. UPDATE 1-Sanofi held talks with Abbott, Mylan about mature drugs -document

      Headlines

      Wed, 16 Jul 2014

      * Portfolio has sales of 2.1 bln eur, enterprise value 6.3 bln eur

    10. UPDATE 2- Mylan to buy Abbott generics, cut taxes, in $5.3 bln deal

      Headlines

      Mon, 14 Jul 2014

      (Adds analyst comments, details of deal, company background, stock prices)

    « Prev12345Next »
    Content Partners